Home›Trial›NCT07425392
🔬NCT07425392Phase 3RECRUITING

Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination

Study Summary

The study will evaluate the safety, tolerability, and immunogenicity of VAX-31 in adults ≥50 years of age.

Conditions
Pneumococcal Vaccines
Interventions / Drugs
31-valent pneumococcal conjugate vaccinePCV20
View on ClinicalTrials.gov ↗
Sponsor
PCVX
Vaxcyte Inc
Vaccines
F29/100
Study Details
Enrollment720 participants
Primary Completion—
Lead SponsorVaxcyte, Inc.
Data Retrieved2026-04-11 04:24:14.205321+00:00
Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.